menu
    • menu

    Company profile for Vogenx

    NEW Drugs in Dev: 1
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Vogenx is a clinical-stage life science and drug development company focused on the development of mizagliflozin for the treatment of post-bariatric hypoglycemia (PBH). Mizagliflozin is a small molecule inhibitor of sodium-glucose transporter 1 (SGLT1) with a site of action in the intestinal lumen. Mizagliflozin has been administered to over 500 subjects in 9 clinical studies. The Vogenx team has significant discovery and deve...
    Vogenx is a clinical-stage life science and drug development company focused on the development of mizagliflozin for the treatment of post-bariatric hypoglycemia (PBH). Mizagliflozin is a small molecule inhibitor of sodium-glucose transporter 1 (SGLT1) with a site of action in the intestinal lumen. Mizagliflozin has been administered to over 500 subjects in 9 clinical studies. The Vogenx team has significant discovery and development experience in metabolic diseases, including metabolic-related rare diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    VogenxUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3920 South Alston Ave, Durham, NC 27713
    Telephone
    Telephone
    +1 9196595677
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vogenx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vogenx-inc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vogenx to Present Mizagliflozin Phase 2 Data at ENDO 2025
    Vogenx to Present Mizagliflozin Phase 2 Data at ENDO 2025

    15 Apr 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/vogenx-inc-to-present-phase-2-clinical-data-on-mizagliflozin-at-the-e-1015263

    ACCESSWIRE
    15 Apr 2025
    Share Share
    Vogenx Announces Positive Phase 2 Results For Mizagliflozin In Hypoglycemia
    Vogenx Announces Positive Phase 2 Results For Mizagliflozin In Hypoglycemia

    26 Jun 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=882166&lang=en

    ACCESSWIRE
    26 Jun 2024
    Share Share
    Vogenx Completes Dosing of Last Patient in Ph 2 Study of Mizagliflozin
    Vogenx Completes Dosing of Last Patient in Ph 2 Study of Mizagliflozin

    02 Apr 2024

    // ACCESSWIRE

    https://www.accesswire.com/849173/vogenx-completes-dosing-of-last-patient-in-phase-2-clinical-study-of-mizagliflozin-for-the-treatment-of-post-bariatric-hypoglycemia

    ACCESSWIRE
    02 Apr 2024
    Share Share
    Vogenx Completes Enrollment of Phase 2 Trial of Mizagliflozin
    Vogenx Completes Enrollment of Phase 2 Trial of Mizagliflozin

    15 Feb 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=833986&lang=en

    ACCESSWIRE
    15 Feb 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search